Brokers Issue Forecasts for Curis’ Q1 Earnings (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Curis in a report issued on Friday, March 20th. HC Wainwright analyst S. Nik forecasts that the biotechnology company will post earnings of ($0.19) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Curis’ current full-year earnings is ($7.12) per share. HC Wainwright also issued estimates for Curis’ Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.24) EPS.

Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, March 19th. The biotechnology company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $3.25 million.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.00.

Curis Stock Down 3.4%

Curis stock opened at $0.72 on Monday. The company has a 50 day moving average of $0.97 and a 200-day moving average of $1.23. Curis has a twelve month low of $0.67 and a twelve month high of $3.13. The stock has a market capitalization of $9.82 million, a PE ratio of -0.60 and a beta of 3.02.

Institutional Trading of Curis

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC grew its stake in Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Curis during the 4th quarter worth approximately $26,000. Squarepoint Ops LLC raised its stake in shares of Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 8,973 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Curis by 2,883,237.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 230,659 shares during the last quarter. Finally, Armistice Capital LLC boosted its holdings in shares of Curis by 8.7% in the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 78,265 shares during the last quarter. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.